ICON Public’s (ICLR) “Outperform” Rating Reaffirmed at Leerink Partners

Leerink Partners reissued their outperform rating on shares of ICON Public (NASDAQ:ICLR) in a report issued on Tuesday morning,Benzinga reports. They currently have a $255.00 target price on the medical research company’s stock, down from their prior target price of $270.00.

Several other research analysts have also issued reports on the company. JPMorgan Chase & Co. cut their price target on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. TD Cowen reduced their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Robert W. Baird lowered shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price objective on the stock. in a research note on Thursday, October 24th. Finally, The Goldman Sachs Group lowered their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $302.91.

ICON Public Stock Up 4.5 %

ICON Public stock opened at $195.60 on Tuesday. The company has a market capitalization of $16.14 billion, a PE ratio of 21.81, a PEG ratio of 1.40 and a beta of 1.25. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72. The firm’s fifty day moving average is $263.10 and its 200 day moving average is $299.72. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the firm posted $3.10 earnings per share. As a group, sell-side analysts predict that ICON Public will post 13.43 EPS for the current fiscal year.

Institutional Trading of ICON Public

Hedge funds have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ICON Public during the 2nd quarter valued at $54,000. ORG Partners LLC purchased a new stake in ICON Public during the second quarter worth about $59,000. GAMMA Investing LLC raised its position in ICON Public by 50.0% in the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after acquiring an additional 87 shares during the period. EverSource Wealth Advisors LLC boosted its stake in ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 42 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its position in shares of ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after acquiring an additional 226 shares during the period. 95.61% of the stock is currently owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.